Factor XIa Inhibitors: Dosing Guidance Not Yet Established
Neither asundexian nor milvexian currently has FDA-approved dosing recommendations for clinical use, as both remain investigational agents without regulatory approval for anticoagulation in any indication, including patients with high bleeding risk or renal impairment.
Current Development Status
Asundexian
The oral factor XIa inhibitor asundexian has been studied in phase 2 and 3 trials at doses of 20 mg and 50 mg once daily 1. However, the pivotal OCEANIC-AF phase 3 trial comparing asundexian to apixaban for stroke prevention in atrial fibrillation was prematurely discontinued due to inefficacy 2. This represents a critical setback, as the drug failed to demonstrate non-inferiority to standard anticoagulation despite showing promising bleeding profiles in earlier studies.
In the PACIFIC-AF phase 2 study, asundexian 50 mg once daily achieved 92% inhibition of factor XIa activity at trough concentrations and demonstrated significantly lower bleeding rates compared to apixaban (incidence proportion ratio 0.16,90% CI 0.01-0.99) 1. Despite this favorable safety signal, the lack of efficacy in phase 3 means no validated dosing exists for clinical practice.
Milvexian
Milvexian has been evaluated at 25 mg twice daily and 100 mg twice daily in various clinical contexts 3, 4. The LIBREXIA ACS trial tested milvexian 25 mg twice daily added to antiplatelet therapy after acute coronary syndrome but was terminated for futility after interim analysis showed no reduction in cardiovascular death, myocardial infarction, or stroke (HR 1.05,95% CI 0.91-1.21) 4.
Pharmacokinetic modeling suggested that milvexian 100 mg twice daily would provide more consistent anticoagulation with a peak-to-trough ratio of 1.35 3, but this dose has not been validated in completed phase 3 efficacy trials.
Renal Impairment Considerations
For milvexian specifically, pharmacokinetic data show that moderate renal impairment (eGFR 30-59 mL/min/1.73 m²) increases AUC by 41%, and severe impairment (eGFR <30 mL/min/1.73 m²) increases AUC by 54% compared to normal renal function 5. The half-life extends from 13.8 hours with normal function to approximately 18 hours with moderate or severe impairment 5. However, no dose adjustments have been formally established because the drug lacks approval.
Reversal and Laboratory Monitoring
Unlike established DOACs, factor XIa inhibitors have no specific reversal agents 6. For patients requiring urgent surgery, intravenous tranexamic acid may reduce bleeding risk, and for serious bleeding, tranexamic acid plus low-dose recombinant factor VIIa are suggested based on experience managing factor XI deficiency 6.
Laboratory testing shows that these agents prolong aPTT in a concentration-dependent manner (milvexian > abelacimab > asundexian) but do not significantly affect prothrombin time or Clauss fibrinogen 7. A normal aPTT effectively rules out the presence of asundexian or milvexian 6.
Clinical Context
The provided evidence contains extensive guidance on established anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) with specific dose reductions for renal impairment and bleeding risk 8, 9. For example:
- Apixaban: Reduce from 5 mg twice daily to 2.5 mg twice daily if patient has 2 of 3 criteria: age ≥80 years, weight ≤60 kg, or creatinine ≥1.5 mg/dL 8
- Rivaroxaban: Reduce from 20 mg once daily to 15 mg once daily if CrCl 15-50 mL/min 8
- Dabigatran: Reduce from 150 mg twice daily to 75 mg twice daily if CrCl 15-30 mL/min 8
These established agents remain the appropriate choice for patients requiring anticoagulation with high bleeding risk or renal impairment, as they have proven efficacy, established dose-adjustment algorithms, and available reversal agents (idarucizumab for dabigatran, andexanet alfa for rivaroxaban/apixaban) 6.
Bottom Line
Until factor XIa inhibitors complete successful phase 3 trials and receive regulatory approval with validated dosing regimens, they cannot be recommended for clinical use. The recent trial failures underscore that promising phase 2 safety data do not guarantee clinical efficacy. Patients with high bleeding risk or renal impairment should receive dose-adjusted DOACs according to established guidelines 9, with apixaban often preferred given its favorable bleeding profile and well-defined dose-reduction criteria 8.